Achieve Life Sciences Inc

NASDAQ:ACHV USA Biotechnology
Market Cap
$226.24 Million
Market Cap Rank
#15023 Global
#5961 in USA
Share Price
$4.25
Change (1 day)
+1.19%
52-Week Range
$1.98 - $5.83
All Time High
$6006.00
About

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sop… Read more

Achieve Life Sciences Inc (ACHV) - Total Liabilities

Latest total liabilities as of September 2025: $18.43 Million USD

Based on the latest financial reports, Achieve Life Sciences Inc (ACHV) has total liabilities worth $18.43 Million USD as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Achieve Life Sciences Inc - Total Liabilities Trend (1994–2024)

This chart illustrates how Achieve Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Achieve Life Sciences Inc Competitors by Total Liabilities

The table below lists competitors of Achieve Life Sciences Inc ranked by their total liabilities.

Liability Composition Analysis (1994–2024)

This chart breaks down Achieve Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.14 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.55 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Achieve Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Achieve Life Sciences Inc (1994–2024)

The table below shows the annual total liabilities of Achieve Life Sciences Inc from 1994 to 2024.

Year Total Liabilities Change
2024-12-31 $17.73 Million -14.82%
2023-12-31 $20.82 Million -3.92%
2022-12-31 $21.67 Million +11.27%
2021-12-31 $19.47 Million +546.55%
2020-12-31 $3.01 Million -0.53%
2019-12-31 $3.03 Million -7.74%
2018-12-31 $3.28 Million +63.04%
2017-12-31 $2.01 Million -76.33%
2016-12-31 $8.50 Million -59.05%
2015-12-31 $20.77 Million -6.58%
2014-12-31 $22.23 Million +20.32%
2013-12-31 $18.48 Million +16.88%
2012-12-31 $15.81 Million -57.42%
2011-12-31 $37.12 Million -18.93%
2010-12-31 $45.79 Million -0.50%
2009-12-31 $46.02 Million +1027.14%
2008-12-31 $4.08 Million -69.40%
2007-12-31 $13.34 Million -47.57%
2006-12-31 $25.45 Million +12.37%
2005-12-31 $22.65 Million +548.37%
2004-12-31 $3.49 Million +61.84%
2003-12-31 $2.16 Million -2.34%
2002-12-31 $2.21 Million +84.42%
2001-12-31 $1.20 Million -79.34%
2000-12-31 $5.80 Million -28.39%
1999-12-31 $8.10 Million -28.32%
1998-12-31 $11.30 Million +8.65%
1997-12-31 $10.40 Million +4.00%
1996-12-31 $10.00 Million +14.94%
1995-12-31 $8.70 Million -28.69%
1994-12-31 $12.20 Million --